2021 KUMC Virtual Multidisciplinary Oncology Review
IO Updates for MSS & HER2 Overexpression CRC: Nivo Alone or in Combination for CC, Regorafenib+Nivo for mCRC, Bev+Chemo, Trastuzumab+Lapatinib/Pertuzumab in HER2+ Disease
Login to view comments.
Click here to Login